Speaker
Oliver Thiel
AMA SITE HEAD EXECUTIVE DIRECTOR, PROCESS DEVELOPMENT, DRUG SUBSTANCE TECHNOLOGIES, AMGEN
Oliver Thiel serves as the site head for Amgen, Massachusetts. Prior to this role he served as lead of the Diversity, Inclusion & Belonging council for the site, and he is an active executive sponsor of several ERGs. Additionally, he leads a group of chemists and engineers, working across the Amgen sites in Cambridge, MA and Thousand Oaks, CA, supporting the commercial process development and commercialization of the Amgen small molecule portfolio.
Oliver joined Amgen in 2003 and moved to Cambridge in 2018 and has held various positions in Process Development. His teams have been accountable for commercial process development, technology transfers and commercial support across synthetic and biologic modalities, supporting multiple commercial products and > 50 clinical development candidates.
Prior to joining Amgen, Oliver was a postdoctoral fellow at Stanford University. He has a M.Sc. degree in chemistry from the Technical University Munich, and a Ph.D. from the Max-Planck-Institut für Kohlenforschung, Mülheim. He also holds an MBA degree from the Fernuniversität Hagen.
Oliver joined Amgen in 2003 and moved to Cambridge in 2018 and has held various positions in Process Development. His teams have been accountable for commercial process development, technology transfers and commercial support across synthetic and biologic modalities, supporting multiple commercial products and > 50 clinical development candidates.
Prior to joining Amgen, Oliver was a postdoctoral fellow at Stanford University. He has a M.Sc. degree in chemistry from the Technical University Munich, and a Ph.D. from the Max-Planck-Institut für Kohlenforschung, Mülheim. He also holds an MBA degree from the Fernuniversität Hagen.
Speaking In
4:15 PM - 5:15 PM
Tuesday, June 6
